Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biogen

118.52
+2.031.74%
Volume:637.30K
Turnover:75.46M
Market Cap:17.35B
PE:10.60
High:119.72
Open:118.12
Low:117.40
Close:116.49
Loading ...

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

GlobeNewswire
·
11 Mar

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2025-03-10

Reuters
·
10 Mar

Unusually active option classes on open March 10th

TIPRANKS
·
10 Mar

BUZZ- Some defensives outperform, even as indexes switch to gains

Reuters
·
08 Mar

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EST on 2025-03-07

Reuters
·
08 Mar

SLDB Stock Rallies 60% in a Month: Here's What You Should Know

Zacks
·
07 Mar

Biogen Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
07 Mar

Biogen (BIIB) Receives a Hold from Bernstein

TIPRANKS
·
06 Mar

Do You Own 15 Stocks Morningstar Calls The Top 'Wealth Destroyers?'

Blockhead
·
03 Mar

Biogen's Alzheimer's Treatment Lecanemab Denied Approval in Australia

MT Newswires Live
·
03 Mar

3 Reasons BIIB is Risky and 1 Stock to Buy Instead

StockStory
·
03 Mar

As baby boomers turn 80, there aren't enough doctors to treat 'emergency levels' of dementia patients

Dow Jones
·
01 Mar

Pfizer quietly made some big DEI changes

Quartz
·
01 Mar

Biogen, Eisai: CHMP Reaffirms Backing of Leqembi Alzheimer's Drug

Dow Jones
·
28 Feb

Biogen, Eisai Say EMA Panel Reaffirms Positive Opinion on Lecanemab

MT Newswires Live
·
28 Feb

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

PR Newswire
·
28 Feb

Biogen, Eisai announces CHMP of EMA reaffirmed positive opinion of lecanemab

TIPRANKS
·
28 Feb

EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug

Reuters
·
28 Feb

EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug

Reuters
·
28 Feb

BRIEF-EMA's CHMP Says Opinion Recommending Marketing Authorisation For Leqembi Not Need To Be Updated

Reuters
·
28 Feb